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Resumen 
Introducción: la disminución de la ingesta alimentaria, la pérdida de apetito y la disfagia son síntomas impactantes en pacientes con cáncer 
del tracto gastrointestinal (TGI). Sin embargo, estos síntomas se han estudiado individualmente o indirectamente al formar parte de cuestionarios 
de calidad de vida o herramientas de riesgo nutricional.
Objetivo: determinar la significancia del análisis combinado de disfagia, apetito e ingesta alimentaria como parámetros de “capacidad” alimentaria 
en pacientes con cáncer del TGI por medio de una nueva escala.
Métodos: estudio piloto transversal en el cual fueron evaluados 41 pacientes con cáncer del TGI utilizando la valoración de “eat-ability” (SEA), 
que se comparó con la valoración global subjetiva generada por el paciente (VGS-GP), la antropometría y métodos de laboratorio.
Resultados: once (27%) pacientes tenían capacidad alimentaria completa (SEA = 0), tres (7%) presentaban capacidad moderada (SEA = 1) 
y 27 (66%), severa (SEA ≥ 2). Se observó una diferencia significativa entre la capacidad alimentaria, cuando se comparó el TGI superior con el 
inferior (p = 0,05). Las SEA con valoración 1 y ≥ 2 fueron analizadas mediante la curva ROC para obtener un poder discriminatorio con respecto 
a VGS-GP (B y C), respectivamente. La sensibilidad y especificidad fue del 80% para ambos, con IC 95%: 0,48-0,95 e IC 95%: 0,63-0,91 res-
pectivamente y área bajo la curva (AUC) de 0,79 (IC 95%: 0,64-0,95) (p = 0,006). Los pacientes con SEA ≥ 2 presentaron un mayor porcentaje 
de pérdida ponderal a los tres (p = 0,001) y seis meses (p < 0,001) en comparación con los pacientes con SEA 0 y 1. La mortalidad también 
fue significativamente mayor (p = 0,01) entre los pacientes con SEA ≥ 2 (77%) y los pacientes gravemente desnutridos por VGS-GP (84%).
Conclusión: al combinar la ingesta alimentaria, la disfagia y la evaluación del apetito, se demostró claramente una capacidad alimentaria 
comprometida que afecta al estado nutricional de los pacientes con tumores en TGI con un mayor riesgo de muerte.
Abstract 
Introduction: decreased food intake, loss of appetite, and dysphagia are relevant symptoms in patients with gastrointestinal tract (GIT) cancer. 
However, these symptoms have been isolated or indirectly assessed when comprising quality of life questionnaires or risk assessment tools.
Objective: to determine whether a combined assessment of dysphagia, appetite and food intake may be used as a parameter of eat-ability (food 
capacity) in patients with GIT cancer.
Methods: a cross-sectional pilot study on 41 patients with GIT cancer were evaluated using a score for “eat-ability” (SEA) as compared to the 
Patient Generated Subjective Global Assessment (PG-SGA), anthropometry and laboratory profile.
Results: eleven (27%) patients had full eat-ability (SEA 0), three (7%) had moderate (SEA 1) and 27 (66%) had poor (SEA ≥ 2) eat-ability, which 
were significantly different, between upper and lower GIT tumors (p ≤ 0.05). By ROC curves, SEA 1 and ≥ 2 showed an 80% for both sensibility 
(95% CI: 0.48-0.95) and specificity (95% CI: 0.63-0.91) to PG-SGA (A and B), with an area under curve (AUC) of 0.79 (95% CI: 0.64-0.95) (p = 
0.006). Patients with SEA ≥ 2 had a significant weight loss within three (p = 0.001) and six months (p < 0.001) when compared to patients with 
SEA 0 and 1. Mortality was also significantly higher (p = 0.01) among patients with critical food capacity by SEA (77%) in severely malnourished 
patients by PG-SGA (84%).
Conclusion: by combining food intake, dysphagia and appetite assessment altogether, a reliable score clearly demonstrated compromised eating 
capacity affecting nutritional status of patients with GIT tumors at a higher risk for death. 
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INTRODUCTION
Decreased food intake is a symptom frequently observed in 
patients with cancer (1). This may be due to a series of metabolic 
changes originated by or as a consequence of the tumor (2-6), 
which induces inflammatory response and changes in hypotha-
lamic function directly affecting appetite (7), thus modifying food 
intake. In addition, antitumor treatment with chemotherapy and/or 
radiotherapy can induce a series of side effects, further decreas-
ing food intake (1).
In patients with esophageal or esophagogastric junction 
(OGJ) cancers, food intake impairment is often caused by dys-
phagia, which is the main symptom related to tumor location (8). 
Dysphagia is also related to a number of factors such as tumor 
resection and addition of chemoradiotherapy treatment (9). All these 
changes can cause relevant weight loss, leading to malnutrition and 
cancer cachexia as well (6), which may be quite remarkable when 
tumors affect the gastrointestinal tract (GIT) (10,11).
Between 48% and 80% of patients with GIT cancer report 
weight loss at the time of diagnosis (11). Unintentional loss of 
10% or more independently of time has been considered as an 
indicator of malnutrition (12).
In addition, malnourished patients presented high risk to devel-
op postoperative complications such as increased infection rate 
(13) and longer hospital staying, with higher morbidity and mor-
tality (14,15). Earlier detection of the risk of malnutrition, as well 
as of the main symptoms that may interfere with food intake, 
allows nutritional interventions to be performed (1) to avoid such 
complications and to reduce cachexia effects.
Inflammatory markers such as C-reactive protein (CRP) are 
used to quantify systemic inflammation (1,16,17). Similarly, some 
scores based on systemic inflammation may be useful in identify-
ing those patients who are at risk for developing cachexia as well 
as to be used as prognostic and predictive factors of treatment 
response (2), such as the modified Glasgow Prognostic Score 
(mGPS) (18) and the neutrophil/lymphocyte ratio (NLR) (2).
There is currently no consensus on the best method for assessing 
nutritional status in cancer patients (19). Thus, distinct parameters 
such as anthropometric measurements of weight, percentage of 
weight loss, body mass index (BMI), laboratory assessment meth-
ods such as serum albumin (1), along with tools such as nutrition 
risk screening (NRS-2002) (20), subjective global assessment 
(SGA) (21) and patient generated subjective global assess-
ment (PG-SGA) (22) have been often used for this purpose.
Anorexia, defined as loss of appetite (7), can be assessed by 
numerous specific tools, such as the Functional Assessment of 
Anorexia/Cachexia Therapy-European Society for Clinical and 
Metabolism score (FAACT-ESPEN score) or the use of visual ana-
logue scales (VAS) (23). 
The VAS is a tool used to translate a subjective sensation into an 
objective quantitative measure. The VAS for appetite is a 100-mm 
line in which ends are anchored to “hunger” and “no hunger” (23) 
or by the phrases “I have no appetite at all” and “my appetite has 
been very good” (7). These tools are presented to patients who 
should self-assess their appetite.
The severity of dysphagia is commonly measured in degrees 
and the scale developed by Atkinson’s et al. is the most widely 
used in patients with esophageal tumors. This scale is divided into 
five levels based on the possibility of swallowing different textures 
of food ranging from ability to eat normal foods to complete inabili-
ty to swallow (24). The internationally well-known guidelines of the 
National Comprehensive Cancer Network (25) for esophageal and 
OGJ also recommends to evaluate dysphagia by a methodology 
similar to that of Atkinson’s et al. 
Changes in dietary intake, loss of appetite and dysphagia com-
promise the nutritional status of cancer patients (1). Although 
these symptoms are relevant to the magnitude of problems affect-
ing GIT cancer, they have been isolated or indirectly assessed 
when comprising quality of life questionnaires, risk assessment 
tools or nutritional status.
To our knowledge, there are no other tools that have been 
particularly developed to assess “food capacity” (eat-ability) as 
a whole in cancer patients. In addition, many tools used abroad 
that evaluate appetite or anorexia have not been validated for the 
Brazilian population and therefore, it may not be possible to com-
pare efficiency and effectiveness of in-country use of these tools.
A more comprehensive way of determining an individual’s 
“eat-ability”, i. e., the ability to eat in the broadest sense, remains 
to be established, considering that ingesting, swallowing and 
having appetite, if assessed altogether, may provide a tool for 
determining “food capacity” or “food performance”. Therefore, 
by developing an instrument that allows assessment of “food 
capacity” particularly weighing each ability itself in patients with 
cancer of the GIT would be of help as an ancillary parameter in 
the assessment of the nutritional status, being at the same time, 
simple, costless and reliable to minor changes as well as feasible 
to be used by any trained healthcare professional.
MATERIAL AND METHODS
This was a cross-sectional, prospective, nested study to a 
broader research project aiming to determine different methods 
of nutritional assessment in outpatients with tumors of the upper 
gastrointestinal tract, approved by the Ethics Committee of the 
Hospital de Clínicas de Porto Alegre (HCPA) University Attached 
Hospital, Southern Brazil (IRB #13-0520), according to the criteria 
set by the Declaration of Helsinki. This study is based on a con-
venience sample selected in a consecutive manner and is part 
of the research line of the Southern Surgical Oncology Research 
Group (SSORG).
In this study, 41 patients (21 males, 20 females), over 40 years, 
with a mean age of 59 years, with malignant neoplasms of the 
upper (esophagus, stomach, pancreas, gallbladder and liver) or 
lower GIT (colon, rectum), treated at the Department of Surgery, 
HCPA University Attached Hospital, from October 2013 to June 
2016, who consented in writing to participate in the study were 
included.
Patients with comorbidities such as severe renal failure, liver 
dysfunction and active infection were excluded. Demographics, 
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clinical and laboratory data were retrieved from electronic patient 
records at the first outpatient appointment. Serum albumin, 
C-reactive protein (CRP) and whole blood counts for neutrophil/
lymphocyte ratio (NLR) analysis were considered out of normal 
range when values were lower than < 3.5 g/dl, > 10 mg/l and 
≥ 5, respectively.
Anthropometric data, including current weight (kg) and height (m), 
percentage of unintentional weight loss (%WL) and body mass 
index (BMI; kg/m²) were also noted. Weight and height were 
checked using a previously calibrated platform-type Welmy® dig-
ital scale and measuring ruler. Adult and elderly tables proposed 
by the World Health Organization (WHO) (26) and Lipschitz (27) 
were used to classify BMI, respectively.
Adults (from 40 up to 60 years) with BMI ≥ 25 kg/m² and elder 
patients with BMI > 27 kg/m² were considered as overweight. 
Adult patients with BMI < 18.5 kg/m² and elder ones with BMI 
< 22 kg/m² were classified as malnourished. Usual weight (UW) 
as reported was used to determine the %WL in relation to the 
current weight (CW) and determined at one, three and six months 
according to Blackburn et al. (28).
A validated Portuguese version of the Ottery’s PG-SGA (1996) 
was used to determine nutritional status specifically for oncology 
patients (22). PG-SGA results were classified as A (well nourished), 
B (moderately malnourished) and C levels (severely malnourished). 
Cancer diagnosis, staging and neoadjuvant therapies such as che-
mo- or radiotherapy when applied were also obtained from patient 
electronic charts. The classification of the American Joint Committee 
on Cancer (AJCC) was used to evaluate clinical staging (29).
The evaluation of appetite, food intake and dysphagia was per-
formed separately; later, in an attempt to better determine the role 
of appetite, ability to ingest and swallow food as a broader food 
parameter, these abilities were evaluated altogether, generating 
a weighed scale which was called score of “eat-ability” (SEA).
To assess appetite changes, a visual analogue scale (VAS), 
adapted from the pain VAS (30) and composed of faces and colors 
on backward positions to pain VAS, was used. In this scale, 0 to 
2 scores were considered as appetite loss; 3 to 7, as moderate 
appetite; and from 8 to 10 points, as normal appetite.
To determine food intake, a questionnaire-based tool of the 
Nutrition Day Worldwide (31), consisting of illustrative pictures 
ranging empty plates and glasses through full plates and glasses, 
where the patient points out which range better refers to current 
intake (i. e., 100% for full intake, 75% or more than half, half 
or up to 50%, 25% or less than half and 0% for nil), was used. 
Ingestion less than 60% was considered as impaired or poor; 
between 60% and 75%, as moderate intake; and more than 75%, 
as normal intake.
The severity of dysphagia was classified according to the recom-
mendations by the National Comprehensive Cancer Network (25) 
as being grade 0 for no swallowing problems, grade 1 for swal-
lowing of small pieces of solid foods, grade 2 and 3 for swallowing 
semisolid foods or liquid foods only, respectively, and grade 4 
for patients unable to swallow.
For food intake, appetite and dysphagia, 0, 1 or 2 points were giv-
en according to the severity of the symptoms presented. Zero was 
assumed to be regular appetite, regular food intake and grade 0 
or 1 dysphagia; similarly, 1 point was assumed to be moderate 
appetite, moderate food intake and grade 2 dysphagia; and score 2 
was used for inappetence, poor or impaired food intake and grade 
3 or 4 dysphagia. 
The sum of those assigned points was used then to define the 
levels of eat-ability (0 to 2) as the SEA, in order to define the need for 
specific nutritional and therapeutic intervention. SEA 0 was consid-
ered for full eat-ability, indicating no nutritional intervention required 
at the time of assessment, but re-assessment on a regular basis 
during treatment. SEA 1 was considered as moderate or impaired 
eat-ability, indicating a need of nutritional intervention, while SEA 
≥ 2 was considered to be critical eat-ability, indicating that both, 
specific nutritional and therapeutic approaches are needed.
Deaths were noted from patient records or by telephone contact 
to family members.
Statistical analyses included Chi-squared and Pearson’s tests, 
with continuity or Fisher’s exact correction by Monte Carlo simu-
lation for categorical variables, while the adjusted residue test was 
applied to test remaining correlations. For quantitative assess-
ment, the Shapiro-Wilk test was used to verify data symmetry. In 
the case of normal distribution, Student’s t test for independent 
variables or analysis of variance (ANOVA) corrected by Tukey 
test were used. In case of asymmetry, Mann-Whitney and Krus-
kal-Wallis tests were applied, respectively.
SEA cut-off level (up to 1 or more than 2) was determined by the 
receiver operating characteristic (ROC) curve to get discriminatory 
power to the PG-SGA (B and C nutritional status, respectively). 
Statistical Package Social Sciences for Windows version 21.0 
was used to analyze data, considering a significance level of 5% 
(p ≤ 0.05).
RESULTS
Of the 41 patients included, 30 (73%) had upper and eleven 
(27%) had lower GIT tumors. Among the most prevalent tumors, in 
15 (37%) cases the primary tumor was located in the esophagus, 
eleven (27%) in the stomach and in the colon in eight (19%) cas-
es. Most of the patients presented at advanced stages of disease, 
with 18 (64%) classified as stage IV and seven (25%), as stage 
IIIa or IIIb. The results of these analyses are described in table I.
According to the nutritional status (Table II), three fourths of 
the patients had some degree of malnutrition, 12 (29%) were 
moderately malnourished (PG-SGA B) with almost half of them 
(46%) severely malnourished (PG-SGA C), while BMI showed 
only 13 (32%) malnourished patients. Similarly, only six (17%) 
patients had decreased serum albumin levels. Increased weight 
loss at three and six months prior to the outpatient assessment 
was observed. However, detailed analyses of weight loss at one, 
three and six months were not significant (NS).
Regarding inflammatory markers (CRP and NLR), patients with 
increased CRP levels approximately duplicated the number of 
patients with altered NLR (74% vs 39%). This analysis is pre-
sented in table II.
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By stratifying upper and lower GIT tumors, statistical signifi-
cance values were found for BMI (Table II), indicating that patients 
with upper GIT tumors had decreased mean BMI values when 
compared to patients with lower GIT tumors (p = 0.001). Malnu-
trition was more prevalent in patients with malignant neoplasms 
of upper GIT (n = 12; 40%), while most patients with lower GIT 
malignancies were overweight (p = 0.003). When evaluated by 
PG-SGA, 57% of patients with upper GIT tumors were considered 
as severely malnourished (category C), while only 18% of patients 
with lower GIT tumors did (NS).
Isolate assessment of dysphagia, appetite or food intake 
failed to demonstrate eat-ability changes between groups (NS). 
Table I. Characteristics of the sample
Variables
Total sample
(n = 41)
Upper GIT
(n = 30)
Lower GIT
(n = 11)
p
Age, mean (SD); years 58.9 (11.9)  60.4 (12.0) 54.8 (11.3)  0.191
Sex, n (%)
 Male 21 (51.2) 18 (60.0) 3 (27.3) 0.088
 Female 20 (48.8) 12 (40.0) 8 (72.7)
Race, n (%)
 White 36 (87.8) 25 (86.2) 10 (90.9) 1.000
 Non white 5 (12.2) 4 (13.8) 1 (9.1)
Tumor location, n (%)
 Esophagus 15 (36.6) 15 (50.0) - < 0.001
 Stomach 11 (26.8) 11 (36.7) -
 Liver 2 (4.9)  2 (6.7) -
 Pancreas 1 (2.4) 1 (3.3) -
 Gallbladder 1 (2.4) 1 (3.3) -
 Colon 8 (19.5) - 8 (72.7)
 Rectum 3 (7.3) - 3 (27.3)
Comorbidities, n (%)
 Nil 28 (68.3) 20 (66.7) 8 (72.7) 0.790
 Hypertension 6 (14.6) 4 (13.3) 2 (18.2)
 Type 2 diabetes 3 (7.3) 2 (6.7) 1 (9.1)
 Multiple 3 (7.3) 3 (10.0) 0 (0.0)
 Dyslipidemia 1 (2.4) 1 (3.3) 0 (0.0)
Clinical stage, n (%)
 IB 1 (3.6) 1 (5.6) 0 (0.0) 0.022
 IIB 2 (7.1) 1 (5.6) 1 (10.0)
 IIIA 2 (7.1) 0 (0.0) 2 (20.0)*
 IIIB 5 (17.9) 1 (5.6) 4 (40.0)*
 IV 18 (64.3) 15 (83.3)* 3 (30.0)
Neoadjuvant treatment, n (%)
 Chemotherapy 5 (12.8) 2 (7.1) 3 (27.3) 0.125
 Radiotherapy 4 (10.5) 3 (11.1) 1 (9.1) 1.000
 Hospital staying, length (days)† 17 (9.5-24) 17 (8.5-30) 14 (11-24) 0.783
Death, n (%)
 Yes 25 (61.0) 19 (63.3) 6 (54.5) 0.723
 No 16 (39.0) 22 (36.7) 35 (45.5)
n (%): values are presented in number and percentage, unless otherwise shown. *Statistically significant association by the test of residuals adjusted to 5% of 
significance. †Described by median (25-75 percentiles). Staging was classified according to the American Joint Committee on Cancer (AJCC, 7th ed. 2010).
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However, when ranked and analyzed altogether by the SEA, a 
statistically significant change in food capacity was demonstrated 
when comparing upper and lower GIT tumors (p = 0.05). This 
analysis is shown in table III.
SEA cut-off points of up to 1 or 2 or more, i. e., moderate 
and critical food capacity, respectively, were analyzed by the ROC 
curve to get discriminatory power regarding PG-SGA moderate 
(B) and severe (C) malnutrition, both, sensitivity and specificity by 
SEA reached 80% with a 95% CI of 0.48-0.95 and 0.63-0.91, 
respectively, and an AUC estimated at 0.79 (95% CI: 0.64-0.95; 
p = 0.006). This analysis is depicted in figure 1.
Patients with a SEA 2 or higher presented a significantly greater 
weight loss at three (p = 0.001) and six (p < 0.001) months 
as compared to patients with SEA 0 or 1. Also, all or lower GIT 
patients with full (SEA 0) and moderate (SEA 1) food capacity 
had a higher prevalence of overweight, as opposed to those with 
critical food capacity by the BMI (Table IV).
Some SEA 0 patients (54.5%) showed moderate malnutrition 
(PG-SGA B), while those with SEA 1 and SEA > 2 were either 
well nourished (PG-SGA A) or severely malnourished (PG-SGA C), 
respectively.
The incidence of deaths was significantly higher in severely 
malnourished (PG-SGA C) patients and in SEA ≥ 2 (both p = 0.01) 
as well, as shown in figure 2.
DISCUSSION
Different parameters have been used to evaluate nutritional 
status in cancer patients (10). The Consensus of the North Amer-
ican Society of Surgeons and the European Society for Clinical 
Nutrition and Metabolism suggested serum albumin for assessing 
nutritional risk in the preoperative period (14,32). However, proper 
determination of such measure is often difficult because non-nu-
tritional factors involved, such as inflammation (33) and hydration 
(10), prevent its use as a marker of risk and nutritional status.
Similarly, considering BMI as the only standard pattern to define 
nutritional status seems unsuitable, since BMI does not take body 
composition into account, expressing body weight that may lead 
to misdiagnosing malnutrition (19).
Several tools can be used for risk assessment and nutritional sta-
tus in clinical practice (19). Although there is no agreement yet (19), 
Table II. Anthropometric data and inflammatory markers
Variables
Total sample
(n = 41)
Upper GIT
(n = 30)
Lower GIT
(n = 11)
p
Weight loss, mean % (SD) 
 1 month 2.2 (5.4) 1.9 (5.4) 3.1 (5.6) 0.539
 3 months 7.9 (9.0) 8.8 (9.4) 5.4 (8.2) 0.297
 6 months 10.2 (8.7) 11.2 (8.8) 7.6 (8.1) 0.242
 BMI (kg/m2), Mean (SD) 23.8 (5.4) 22.1 (4.7) 28.3 (4.5) 0.001
Classification by BMI
 Malnutrition 13 (31.7) 12 (40.0) 1 (9.1) 0.003
 Normal 12 (29.3) 11 (36.7) 1 (9.1)
 Overweight 16 (39.2) 7 (23.3) 9 (81.8)
PG-SGA
 A 10 (24.4) 5 (16.7) 5 (45.5) 0.062
 B 12 (29.3) 8 (26.7) 4 (36.4)
 C 19 (46.3) 17 (56.7) 2 (18.2)
NLR (n = 36)
 < 5 22 (61.1) 16 (59.3) 6 (66.7) 1.000
 ≥ 5 14 (38.9) 11 (40.7) 3 (33.3)
Albumin (g/dl) (n = 35) 
 < 3.5 6 (17.1) 4 (16.7) 2 (18.2) 1.000
 ≥ 3.5 29 (82.9) 20 (83.3) 9 (81.8)
CRP (mg/l) (n = 31)
 ≤ 10 8 (25.8) 4 (19.0) 4 (40.0) 0.381
 > 10 23 (74.2) 17 (81.0) 6 (60.0)
n (%): values are presented in number (n) and percentage (%), unless otherwise shown. BMI: body mass index; PG-SGA: Patient Generated Subjective Global 
Assessment; NLR: neutrophil/lymphocyte ratio; CRP: C-reactive protein.
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PG-SGA, SGA and Minimal Nutrition Assessment (MNA) are the tools 
frequently used for nutritional assessment of oncological patients (14).
In our study, there was an overall disagreement among nutri-
tional assessment by PG-SGA, BMI or by serum albumin. These 
findings further support the fact that either BMI or serum albumin 
alone did not prove to be consistent methods for this purpose (19), 
since PG-SGA allowed the identification of malnutrition in 76% of 
the cases, less than a third of the patients were malnourished by 
BMI and a little more than one-sixth, by serum albumin.
Likewise, BMI, although significantly reduced in patients with 
upper GIT tumors and less decreased in those with lower GIT 
tumors, failed to categorically identify malnutrition, as BMI did not 
distinguish patients with critical food capacity. On the other hand, 
by PG-SGA, more than three fourths of malignant neoplasms of 
the upper GIT cases presented malnutrition and more than half of 
those with lower GIT cancer had the same diagnosis.
The results for dysphagia by the Atkinson’s scale, in a cohort 
of 110 cases of esophageal cancer, showed 40% of patients 
presented grade 0 and 1 and 60% presented grades 2 to 4 (24). 
Similar results were obtained by SEA, as 47% of patients with 
upper GIT cancer had grade 0 and 1 of dysphagia and 53%, 
grades 2 to 4. Besides esophagus tumors, other upper GIT tumors, 
such as those of the liver, pancreas, gallbladder and stomach 
were included in the SEA and, since dysphagia is uncommon in 
these tumors (8), SEA results for dysphagia to upper GIT tumors 
in general proved to be reliable. 
Table III. Data on food capacity and the score of “eat-ability”
Variables
Total sample
(n = 41)
Upper GIT
(n = 30)
Lower GIT
(n = 11)
p
Dysphagia
 Grade 0/1 21 (51.2) 14 (46.7) 7 (63.6) 0.210
 Grade 2 7 (17.1) 7 (23.3) 0 (0.0)
 Grade 3/4 13 (31.7) 9 (30.0) 4 (36.4)
Appetite
 8-10 17 (41.5) 11 (36.7) 6 (54.5) 0.476
 3-7 16 (39.0) 12 (40.0) 4 (36.4)
 0-2 8 (19.5) 7 (23.3) 1 (9.1)
Food intake
 > 75% 19 (47.5) 12 (41.4) 7 (63.6) 0.289
 60-75% 4 (10.0) 4 (13.8) 0 (0.0)
 < 60% 18 (43.9) 14 (46.7) 4 (36.4)
 Points of “eat-ability”* 3 (0-4) 3 (1.5-4) 1 (0-4) 0.294
Score of “eat-ability”
 0 11 (26.8) 6 (20.7) 5 (45.5) 0.050
 1 3 (7.3) 1 (3.3) 2 (18.2)
 ≥ 2 27 (65.9) 23 (76.7) 4 (36.4)
n (%): values are presented in number and percentage, unless otherwise shown. *Median (25-75 percentiles).
Figure 1. 
SEA cut-off points (1 and ≥ 2) determined by the ROC curve in relation to ASG-PPP 
(B and C). The sensitivity by SEA was 80% (95% CI: 0.48-0.95). Specificity was 
80% (95% CI: 0.63-0.91), with an area under the ROC curve (AUC) of 0.79 (95% 
CI: 0.64-0.95, p = 0.006).
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Similarly, regarding appetite and food intake, when evaluat-
ed independently, no discriminatory power was found between 
upper and lower tumors. However, it can be observed that 63% 
vs 60% of patients with upper GIT tumors showed alterations, 
respectively, while these figures were 45% vs 36% for lower 
GIT tumors. 
The SEA appetite scale showed appetite loss in 23% of 
patients with upper GIT cancer, same as it was found in a study 
that applied the appetite VAS as one of the tools used to com-
pare instruments in the assessment of inpatients anorexia (23). 
In this study, 23% of the patients were diagnosed with anorexia 
by the appetite VAS, against only 10% of the cases by the 
FAACT-ESPEN score (23).
Up to date, there is still no tool that can be considered as a 
“gold standard” for diagnosing anorexia in cancer patients (7). 
Moreover, some studies indicated that VAS for appetite in clinical 
practice better suits the need to track changes over time rath-
er than diagnosing anorexia on a specific day (23). However, in 
developing countries, the VAS for determining appetite turns into 
a simpler, more practical, quicker and easier tool to be perceived 
by the patient when compared to questionnaires with multiple 
domains, often difficult to understand.
Table IV. Association of anthropometric data and inflammatory markers by SEA
Variables
Food capacity - Score of eat-ability (SEA)
p
Full (0) Moderate (1) Critical (≥ 2)
Weight loss, mean % (SD)
 1 month 0.1 (3.6) -0.9 (1.1) 3.3 (6.0) 0.154
 3 months 2.2 (6.7)† -0.9 (1.1)† 11.9 (8.4)‡ 0.001
 6 months 4.7 (7.2)† -0.9 (1.1)† 14.5 (6.6)‡ < 0.001
 BMI (kg/m2), mean (SD) 25.4 (5.5) 28.5 (0.1) 22.9 (5.2) 0.130
Classification by BMI
 Malnutrition 3 (27.3) 0 (0.0) 9 (34.6) 0.026
 Normal 1 (9.1) 0 (0.0) 11 (42.3)*
 Overweight 7 (63.6)* 3 (100)* 6 (23.1)
PG-SGA
 A 5 (45.5) 3 (100)* 2 (7.7) < 0.001
 B 6 (54.5)* 0 (0.0) 6 (23.1)
 C 0 (0.0) 0 (0.0) 18 (69.2)*
NLR
 < 5 8 (80.0) 2 (66.7) 12 (54.5) 0.381
 ≥ 5 2 (20.0) 1 (33.3) 10 (45.5)
Albumin (g/dl)
 < 3.5 1 (10.0) 0 (0.0) 5 (22.7) 0.481
 ≥ 3.5 9 (90.0) 3 (100) 17 (77.3)
CRP (mg/l)
 ≤ 10 2 (20.0) 2 (66.7) 4 (23.5) 0.251
 > 10 8 (80.0) 1 (33.3) 13 (76.5)
n (%): values are presented in number and percentage, unless otherwise shown. BMI: body mass index; PG-SGA: Patient Generated Subjective Global Assessment; 
NLR: neutrophil/lymphocyte ratio; CRP: C-reactive protein. *Statistically significant association by the test of the residuals adjusted to 5% of significance. †,‡Equal 
figures do not differ by the Tukey test at 5% significance. 
Figure 2. 
Incidence of death according to food capacity as determined by the SEA and 
PG-SGA (both p = 0.01).
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In the SEA, determining the evaluation of intake by a combined 
VAS on the percentage of estimated solids and liquids taken also 
allowed greater intake perception by patients as a whole. One of 
the criteria to indicate enteral nutritional therapy in cancer patients 
is food intake under 60% of their nutritional needs for more than 
one to two weeks (1). This would be the case in 47% and 36% of 
patients with upper and lower GIT tumors, respectively, by using 
the SEA, resulting in a quick and simple way that provides health 
professionals with a reliable assessment on patient daily food 
compliance and clearly avoiding misinterpretation. 
When these parameters (dysphagia, appetite and food intake) 
were evaluated altogether, it became easier to consider that dys-
phagia is directly involved with intake and secondary and indirect-
ly, with appetite, just as appetite loss is directly implicated with 
less food intake. SEA allowed better judgment on “eat-ability” 
(food capacity) among upper and lower GIT patients, who are 
possibly at increased risk of malnutrition.
Malnutrition might be detected in up to 87% of patients with GIT 
cancer, depending on tumor site and stage (11). In SEA, critical 
food capacity (SEA ≥ 2) was associated to 92% of malnourishment 
cases, being also reliably associated with weight loss at three and 
six months previously, when compared to full and moderate food 
capacity (SEA 0 or 1), respectively.
Blackburn et al. considered as severe unintentional weight loss 
greater than 5%, 7.5% and 10% at one, three and six months, 
respectively (28), as unintentional weight loss > 10% has been 
considered to be an indicator of nutritional risk (12). In our study, 
SEA ≥ 2 was consistent with weight loss greater than 10% at 
three and six months, showing the role of SEA as a predictor of 
weight loss and high nutritional risk.
Some discrepancy between full and moderate “eat-ability” in 
moderately undernourished and well-nourished patients, respec-
tively, was due to a type II sampling error, since there were no 
cases in three subgroups of those categories. Although all cases 
classified as critical “eat-ability” were severely malnourished, 
a greater sample is still needed to validate this combined SEA. 
Despite this, there was a greatly “eat-ability” impairment among 
patients who died, who were greatly malnourished. Nevertheless, 
the role of “eat-ability” and malnutrition on death risk requires 
further studies on a large sample, since most patients were in 
advanced stages of the disease (stages III and IV).
Another deterrent factor in the study is that most of the patients 
died after hospital discharge, making it difficult to establish if 
death was directly related to the tumor or to the comorbidities.
Perspectives point out to increase cases evaluated by SEA 
and to compare it with inflammatory parameters, most probably 
with c-reactive protein (CRP), since SEA and CRP were similarly 
increased and CRP was twice NLR positive, and to better deter-
mine the role of SEA as a nutritional risk ancillary.
In conclusion, the combined evaluation of food intake, dyspha-
gia and appetite (SEA) was reliable in clearly identifying patients 
with impaired “eat-ability” in more than half and in more than 
three fourths of those with lower and upper GIT tumors, respec-
tively, that significantly affect nutritional status and risk of death 
of patients with GIT tumors.
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